IMMX — Immix Biopharma Inc
NASDAQ · Healthcare · Biotechnology
$13.97
-$0.04 (-0.25%)
Immix Biopharma Inc (IMMX) is a biotechnology company listed on NASDAQ. It is led by Ilya Rachman M.B.A., M.D., Ph.D., based in 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064, with about 21 employees. Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Net income was -$7.6M. IMMX currently screens at market cap $640.7M.
Use this IMMX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IMMX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IMMX SEC filings page. Lician reads the product cache first so this HTML stays unique to Immix Biopharma Inc even when a live quote feed is slow.
About Immix Biopharma Inc
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
IMMX Key Statistics
Market Cap
$640.71M
Volume
1.38M
Previous Close
$14.47
Day Range
$13.80 – $14.55
EPS
-$0.76
Revenue
$0.00
Net Income
-$21.70M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
21
IMMX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$21.70M | -$15.60M | -$8.23M |
| EPS (Diluted) | -$0.76 | -$0.89 | -$0.59 |
Total Assets
$22.95M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$17.68M
Operating Cash Flow
-$14.60M
Free Cash Flow
$0.00
Immix Biopharma Inc Company Information
- Co-Founder, CEO, Chief Scientific Officer & Chairman
- Ilya Rachman M.B.A., M.D., Ph.D.
- Headquarters
- 11400 West Olympic Boulevard, Los Angeles, CA, United States, 90064
- Website
- www.immixbio.com
- Phone
- 310 651 8041
- IPO / Founded
- 2021-12-16
- Sector
- Healthcare
- Industry
- Biotechnology